Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RMD open

Showing results (101-110 of 2,084) with videos related to

Pageof 209
Sort By:
RMD Open|November 30, 2018
ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)Janet E Pope, Mohammad Movahedi, Emmanouil Rampakakis, et al.
RMD Open|November 30, 2018
Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC studyKaren Holten, Joseph Sexton, Tore K Kvien, et al.
RMD Open|November 30, 2018
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA studyMarco Matucci-Cerinic, Yannick Allanore, Arthur Kavanaugh, et al.
RMD Open|November 30, 2018
DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugsSilva Pukšić, Pernille Bolton-King, Joseph Sexton, et al.
RMD Open|November 30, 2018
Rare diseases under different levels of economic analysis: current activities, challenges and perspectivesSara Cannizzo, Valentina Lorenzoni, Ilaria Palla, et al.
RMD Open|December 20, 2018
Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D studyCarter Thorne, Tsutomu Takeuchi, George Athanasios Karpouzas, et al.
RMD Open|December 20, 2018
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studiesJürgen Braun, Atul Deodhar, Robert Landewé, et al.
RMD Open|December 20, 2018
Systemic lupus erythematosus: state of the art on clinical practice guidelinesFarah Tamirou, Laurent Arnaud, Rosaria Talarico, et al.
RMD Open|November 22, 2019
Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgiaAlen Zabotti, Dennis G McGonagle, Ivan Giovannini, et al.
RMD Open|November 22, 2019
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritisUlf Lindström, Bente Glintborg, Daniela Di Giuseppe, et al.
Pageof 209

Showing results (101-110 of 2,084) with videos related to

Sort By:
Pageof 209
RMD Open|November 30, 2018
ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)Janet E Pope, Mohammad Movahedi, Emmanouil Rampakakis, et al.
RMD Open|November 30, 2018
Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC studyKaren Holten, Joseph Sexton, Tore K Kvien, et al.
RMD Open|November 30, 2018
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA studyMarco Matucci-Cerinic, Yannick Allanore, Arthur Kavanaugh, et al.
RMD Open|November 30, 2018
DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugsSilva Pukšić, Pernille Bolton-King, Joseph Sexton, et al.
RMD Open|November 30, 2018
Rare diseases under different levels of economic analysis: current activities, challenges and perspectivesSara Cannizzo, Valentina Lorenzoni, Ilaria Palla, et al.
RMD Open|December 20, 2018
Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D studyCarter Thorne, Tsutomu Takeuchi, George Athanasios Karpouzas, et al.
RMD Open|December 20, 2018
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studiesJürgen Braun, Atul Deodhar, Robert Landewé, et al.
RMD Open|December 20, 2018
Systemic lupus erythematosus: state of the art on clinical practice guidelinesFarah Tamirou, Laurent Arnaud, Rosaria Talarico, et al.
RMD Open|November 22, 2019
Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgiaAlen Zabotti, Dennis G McGonagle, Ivan Giovannini, et al.
RMD Open|November 22, 2019
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritisUlf Lindström, Bente Glintborg, Daniela Di Giuseppe, et al.
Pageof 209